Park Sunghoon, Cho Goo-Yeong, Kim Sung Gyun, Hwang Yong Il, Kang Hye-Ryun, Jang Seung Hun, Kim Dong-Gyu, Song Young Rim, Bae Young-A, Jung Ki-Suck
Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Sacred Heart Hospital, 896 Anyang, Kyunggi-do 431-070, Republic of Korea.
Crit Care. 2009;13(3):R70. doi: 10.1186/cc7878. Epub 2009 May 15.
Limited data are available regarding the diagnostic and prognostic utility of brain natriuretic peptide (BNP) in patients with chronic kidney disease (CKD) in the intensive care unit (ICU) setting.
All patients with CKD and a serum creatinine (Cr) of 2.0 mg/dl or higher admitted to the ICU between January 2006 and September 2007 were enrolled in this study. The CKD group was divided according to the presence or absence of acute decompensated heart failure (ADHF) into CKD + ADHF and CKD-ADHF groups, respectively. Other patients with ADHF having low Cr (<1.2 mg/dl) in the coronary care unit were also recruited as a control group during the same period. BNP levels at the time of admission (admission BNP) were compared amongst these groups. We then sought to determine whether BNP levels could predict the outcome in patients with CKD.
Of 136 patients with CKD for whom data were available, including 58 on dialysis (42.6%), 81 (59.6%) had ADHF and their estimated glomerular filtration rate (eGFR) was 12.8 +/- 7.3 ml/min/1.73 m2. BNP levels at admission were 2708.6 +/- 1246.9, 567.9 +/- 491.7 and 1418.9 +/- 1126.5 pg/ml in the CKD + ADHF, CKD - ADHF and control groups (n = 33), respectively (P = 0.000). The optimal cutoff level in patients with CKD was 1020.5 pg/ml (area under the curve = 0.944) to detect ADHF from the receiver operating characteristic (ROC) curve. This level was not associated with in-hospital mortality, all-cause death or a composite event (all-cause death and/or new cardiac event). However, a borderline significant association was observed with new cardiac events (hazard ratio (HR) = 4.551; P = 0.078) during the follow-up period (521.1 +/- 44.7 days). Furthermore, continuous variables of BNP and BNP quartiles were significantly associated with new cardiac events in the multivariate Cox model (HR = 1.001, P = 0.041; HR = 2.212, P = 0.018).
The findings suggest that the level of BNP at the time of admission may be a useful marker for detecting ADHF and predicting cardiac events in patients with CKD in the ICU setting.
关于脑钠肽(BNP)在重症监护病房(ICU)环境下对慢性肾脏病(CKD)患者的诊断和预后价值,目前可用数据有限。
纳入2006年1月至2007年9月期间入住ICU且血清肌酐(Cr)≥2.0mg/dl的所有CKD患者。CKD组根据是否存在急性失代偿性心力衰竭(ADHF)分为CKD + ADHF组和CKD - ADHF组。同期冠状动脉监护病房中其他Cr<1.2mg/dl的ADHF患者也被纳入作为对照组。比较这些组入院时的BNP水平(入院BNP)。然后我们试图确定BNP水平是否可以预测CKD患者的预后。
在136例有可用数据的CKD患者中,包括58例接受透析治疗的患者(42.6%),81例(59.6%)有ADHF,其估计肾小球滤过率(eGFR)为12.8±7.3ml/min/1.73m²。CKD + ADHF组、CKD - ADHF组和对照组(n = 33)入院时的BNP水平分别为2708.6±1246.9、567.9±491.7和1418.9±1126.5pg/ml(P = 0.000)。根据受试者工作特征(ROC)曲线,CKD患者中检测ADHF的最佳截断水平为1020.5pg/ml(曲线下面积 = 0.944)。该水平与住院死亡率、全因死亡或复合事件(全因死亡和/或新发心脏事件)无关。然而,在随访期(521.1±44.7天)观察到与新发心脏事件有边缘性显著关联(风险比(HR) = 4.551;P = 0.078)。此外,在多变量Cox模型中,BNP的连续变量和BNP四分位数与新发心脏事件显著相关(HR = 1.001,P = 0.041;HR = 2.212,P = 0.018)。
研究结果表明,入院时的BNP水平可能是检测ICU环境下CKD患者ADHF和预测心脏事件的有用标志物。